Mitchell Rosen, MD

Fertility physician

Dr. Mitchell Rosen is a reproductive endocrinology and fertility expert at the UCSF Center for Reproductive Health. He also is director of the UCSF Fertillity Preservation Center, which helps patients with cancer preserve their ability to have children, despite aggressive cancer treatment.

Rosen earned a medical degree at Saint Louis University and completed residency training in obstetrics and gynecology at the University of Texas Medical Branch in Galveston, Texas. During medical and residency training, he was named the best resident twice and received the Ortho-McNeil Best Resident Teacher Award in 2002. Rosen completed fellowship training in reproductive endocrinology and infertility at UCSF. He was trained in the UCSF embryology laboratory to qualify as a high complexity lab director (HCLD). In addition to caring for patients, he is an associate professor of medicine at UCSF and teaches medical students, residents and fellows.

Clinics

Center for Reproductive Health at Mission Bay
499 Illinois St., Sixth Floor
San Francisco, CA 94158
Phone: (415) 353-7475
Fax: (415) 353-7744

Hours: Monday to Friday
8 a.m. – 4:45 p.m.
Saturday and Sunday apts. available for patients undergoing treatment

Center for Reproductive Health at Mount Zion
2356 Sutter St., Seventh Floor
San Francisco, CA 94115
Phone: (415) 353-7475
Fax: (415) 353-7744

Hours: Monday to Friday
8 a.m. – 4:45 p.m.
Saturday and Sunday apts. available for patients undergoing treatment

Fertility Preservation Program
499 Illinois St., Sixth Floor
San Francisco, CA 94158
Hotline: (415) 353-9115
Fax: (415) 353-7744

Hours: Monday to Friday
8 a.m. – 5 p.m.

Gastrointestinal Oncology Survivorship Program
1825 Fourth St., Fourth Floor
San Francisco, CA 94143
Phone: (415) 353-9888
Fax: (415) 353-9931

Conditions & Treatments

Academic Title

Associate Professor

More about Mitchell Rosen

Education

St. Louis University School of Medicine 1998

Residencies

University of Texas Medical Center, Obstetrics & Gynecology 2002

Fellowships

UCSF Medical Center 2003

Selected Research and Publications

  1. Ahmad AK, Kao CN, Quinn M, Lenhart N, Rosen M, Cedars MI, Huddleston H. Differential rate in decline in ovarian reserve markers in women with polycystic ovary syndrome compared with control subjects: results of a longitudinal study. Fertil Steril. 2018 Mar; 109(3):526-531.
  2. Anaya Y, Mata DA, Letourneau J, Cakmak H, Cedars MI, Rosen MP. Author Correction: A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols. J Assist Reprod Genet. 2018 Feb; 35(2):309.
  3. Winkelman WD, Rosen MP, Mok-Lin E. Fertility Preservation Services for Women With Newly Diagnosed Cancer: A National Assessment. Am J Clin Oncol. 2018 Jan 08.
  4. Huddleston HG, Quinn MM, Kao CN, Lenhart N, Rosen MP, Cedars MI. Women with polycystic ovary syndrome demonstrate worsening markers of cardiovascular risk over the short-term despite declining hyperandrogenaemia: Results of a longitudinal study with community controls. Clin Endocrinol (Oxf). 2017 Dec; 87(6):775-782.
  5. Anaya Y, Mata DA, Letourneau J, Cakmak H, Cedars MI, Rosen MP. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols. J Assist Reprod Genet. 2018 Feb; 35(2):297-307.
  6. Letourneau JM, Sinha N, Wald K, Harris E, Quinn M, Imbar T, Mok-Lin E, Chien AJ, Rosen M. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. Hum Reprod. 2017 Oct 01; 32(10):2123-2129.
  7. Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 08; 165(1):161.
  8. Letourneau JM, Cakmak H, Quinn M, Sinha N, I Cedars M, Rosen MP. Long-term hormonal contraceptive use is associated with a reversible suppression of antral follicle count and a break from hormonal contraception may improve oocyte yield. J Assist Reprod Genet. 2017 Sep; 34(9):1137-1144.
  9. Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 Aug; 165(1):151-159.
  10. ASRM standard embryo transfer protocol template: a committee opinion. Fertil Steril. 2017 04; 107(4):897-900.
  11. Salem WH, Letourneau JM, Chan J, Chan SW, Cedars M, Rosen MP. Cancer survivors of gynecologic malignancies are at risk for decreased opportunity for fertility preservation. Contracept Reprod Med. 2017; 2:12.
  12. Quinn MM, Cakmak H, Letourneau JM, Cedars MI, Rosen MP. Response to ovarian stimulation is not impacted by a breast cancer diagnosis. Hum Reprod. 2017 03 01; 32(3):568-574.
  13. Chan JL, Letourneau J, Salem W, Cil AP, Chan SW, Chen LM, Rosen MP. Regret around fertility choices is decreased with pre-treatment counseling in gynecologic cancer patients. J Cancer Surviv. 2017 Feb; 11(1):58-63.
  14. Shah MS, Letourneau JM, Niemasik EE, Bleil M, McCulloch CE, Rosen MP. The role of in-depth reproductive health counseling in addressing reproductive health concerns in female survivors of nongynecologic cancers. J Psychosoc Oncol. 2016 Jul-Aug; 34(4):305-17.
  15. Bosch E, Labarta E, Kolibianakis E, Rosen M, Meldrum D. Regimen of ovarian stimulation affects oocyte and therefore embryo quality. Fertil Steril. 2016 Mar; 105(3):560-570.
  16. Tran ND, Aghajanova L, Kao CN, Cedars MI, Rosen MP. Impact of pituitary suppression on antral follicle count and oocyte recovery after ovarian stimulation. Fertil Steril. 2016 Mar; 105(3):690-696.
  17. Han B, Herndon CN, Rosen MP, Wang ZJ, Daldrup-Link H. Uterine didelphys associated with obstructed hemivagina and ipsilateral renal anomaly (OHVIRA) syndrome. Radiol Case Rep. 2010; 5(1):327.
  18. Usadi RS, Diamond MP, Legro RS, Schlaff WD, Hansen KR, Casson P, Christman G, Wright Bates G, Baker V, Seungdamrong A, Rosen MP, Lucidi S, Thomas T, Huang H, Santoro N, Eisenberg E, Zhang H, Alvero R. Recruitment strategies in two reproductive medicine network infertility trials. Contemp Clin Trials. 2015 Nov; 45(Pt B):196-200.
  19. Chan JL, Letourneau J, Salem W, Cil AP, Chan SW, Chen LM, Rosen MP. Sexual satisfaction and quality of life in survivors of localized cervical and ovarian cancers following fertility-sparing surgery. Gynecol Oncol. 2015 Oct; 139(1):141-7.
  20. Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. 2015 Aug; 153(1):173-81.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.